Elephas is developing a technology suite to assess how human live tumor fragments (hLTF)™ respond to cancer therapies, aiming to accelerate drug development and empower clinical decision-making.

Elephas

Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs) respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies.

Sands Capital Ventures

WARF Ventures

Northpond Ventures

ARCH Venture Partners

Tao Capital Partners

Moore Strategic Ventures

There's only one week until #SITC2023! Elephas is looking forward to being in San Diego, CA from November 1-5, 2023 to discuss the latest innovations in cancer immunotherapy. https://lnkd.in/gv87X5eQ

Make sure you stop by our booth (#905) to learn more about our biopharma services offerings and how we can work together to change the view of cancer. You can schedule time to speak with Greg Ochs, our VP of Business Development, at the event here: https://lnkd.in/dauHy8DV

We also have some exciting data we're presenting at #SITC2023 that we can't wait to share with you. Stay tuned for more info!

#ChangingtheViewofCancer #PatientCare #Oncology #Immunotherapy #Cancer #Innovation #CancerResearch #ImmunoOncology #CancerImmunotherapy Society for Immunotherapy of Cancer (SITC)

Missed any of our recent posters – such as the one from AACR on label free imaging for rapid assessment of tumor viability in live tumor fragments? Head to our website to check them out now! https://lnkd.in/edtRTzkg

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch #AACR

We're excited to announce that Elephas is a 2023 Wisconsin Innovation Awards winner for Biotechnology! It was an honor to be included alongside such an amazing group of innovative companies in the state. See the announcement and full list of winners here: https://lnkd.in/gp6X6WEd 

Visit our website to learn more about our work and mission here: https://elephas.com/

At Elephas, we are committed to helping pharmaceutical and biotechnology researchers accelerate immunotherapy drug development with a novel approach for assessing response to investigational agents. Powered by Cybrid™, our technology suite is based on human live tumor fragments with the native tumor architecture and immune cells intact.

Visit our website to learn more: https://lnkd.in/eHD5iBCM

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

Elephas is comprised of a group of highly talented people, all committed to developing a transformative diagnostic solution and bringing hope to cancer patients worldwide. Head over to our website to learn more about our mission and how we can all work together to change the view of cancer. https://elephas.com/

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

Did you know that live tumor fragments are taken directly from a patient, which maintains the tumor architecture and tumor microenvironment? Cybrid™, our live tumor diagnostic platform, brings a new dimension of capabilities and insights for biopharmaceutical researchers to understand mechanisms of action and response to cancer immunotherapies.

Learn more here: https://elephas.com/cybrid

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

If you're wondering who we are, what we do, and the role we play in cancer research and drug development, visit our website to see the answers to some of your top asked questions. https://elephas.com/cybrid 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

We know that bringing a new drug to market can be a lengthy process, but it's important that we try to get the right treatments to the right patients. To do this, we need to be able to prove that a treatment is effective for certain types of cancers, and know when it's not. With our research-use Cybrid™ platform, within two weeks* we can measure the impact of a compound on a tumor and its immune cells to help you gain insights and understand the impact on potential patients. 

Visit our website to learn more: https://lnkd.in/eHD5iBCM 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

We understand the importance of clinical trials when it comes to cancer care. Our clinical trials will provide an opportunity to demonstrate the correlation between ex vivo platform and clinical response to immunotherapy. Visit our website to learn more. https://lnkd.in/eFRgqyep 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

At Elephas, we are developing a technology suite to assess how human live tumor fragments respond to various cancer therapies in an effort to enable accurate prediction of clinical treatment outcomes and accelerate drug development in immuno-oncology.

If you're interested in learning more, visit our website: https://elephas.com/cybrid 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

msh id	COM:ELEPHAS
symbol	-
name	Elephas
homepage url	https://elephas.com
country	US
sector	Healthcare
industry	Biotechnology
market	PRIVATE
employee count	135
crunchbase url	https://www.crunchbase.com/organization/elephas-biosciences
linkedin url	https://www.linkedin.com/company/elephasbiosciences
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	52.71
growth score 28	8.97
growth score 90	57.08
growth score 365	56.43

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:ELEPHAS

Elephas

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-